You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 186 Novel analysis strategy of T-cell receptor NGS data to develop patient-specific clonotype panels and detect minimal residual disease (MRD) in T-cell acute lymphoblastic leukemia (T-ALL)

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring and Novel Technologies
186 Novel analysis strategy of T-cell receptor NGS data to develop patient-specific clonotype panels and detect minimal residual disease (MRD) in T-cell acute lymphoblastic leukemia (T-ALL)

Authors

  • Nicholas A Young The Ohio State University Wexner Medical Center, Columbus, OH, USA, Battelle Memorial Institute, Columbus, OH, USA, More than Moore’s (MM): Precision Medicine Solutions, Columbus, OH, USA, Private Health Management, Los Angeles, CA, USA PubMed articlesGoogle scholar articles

Citation

Young NA
186 Novel analysis strategy of T-cell receptor NGS data to develop patient-specific clonotype panels and detect minimal residual disease (MRD) in T-cell acute lymphoblastic leukemia (T-ALL)
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0186

Publication history

  • First published November 2, 2023.
Online issue publication 
November 02, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.